1,3,4-trisubstituted pyrrolidine CCR5 receptor antagonists. Part 2: Lead optimization affording selective, orally bioavailable compounds with potent anti-HIV activity

Authors
Hale, JJ Budhu, RJ Holson, EB Finke, PE Oates, B Mills, SG MacCoss, M Gould, SL DeMartino, JA Springer, MS Siciliano, S Malkowitz, L Schleif, WA Hazuda, D Miller, M Kessler, J Danzeisen, R Holmes, K Lineberger, J Carella, A Carver, G Emini, E
Citation
Jj. Hale et al., 1,3,4-trisubstituted pyrrolidine CCR5 receptor antagonists. Part 2: Lead optimization affording selective, orally bioavailable compounds with potent anti-HIV activity, BIOORG MED, 11(20), 2001, pp. 2741-2745
Citations number
14
Categorie Soggetti
Chemistry & Analysis
Journal title
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
ISSN journal
0960894X → ACNP
Volume
11
Issue
20
Year of publication
2001
Pages
2741 - 2745
Database
ISI
SICI code
0960-894X(20011022)11:20<2741:1PCRAP>2.0.ZU;2-M
Abstract
Investigations of the structure-activity relationships of 1,3,4-trisubstitu ted pyrrolidine human CCR5 receptor antagonists afforded orally bioavailabl e compounds with the ability to inhibit HIV replication in vitro. (C) 2001 Elsevier Science Ltd. All rights reserved.